Sei Investments Co. Decreases Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Sei Investments Co. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 12.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,859 shares of the company’s stock after selling 8,835 shares during the quarter. Sei Investments Co.’s holdings in Moderna were worth $2,572,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB lifted its holdings in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Venturi Wealth Management LLC increased its position in Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after buying an additional 664 shares during the period. Compass Planning Associates Inc purchased a new stake in Moderna in the fourth quarter valued at approximately $37,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after acquiring an additional 389 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after acquiring an additional 388 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Stock Performance

Moderna stock opened at $25.11 on Friday. The firm has a market capitalization of $9.71 billion, a PE ratio of -2.71 and a beta of 2.23. Moderna, Inc. has a one year low of $23.76 and a one year high of $170.47. The stock’s 50 day moving average price is $33.55 and its 200 day moving average price is $43.01.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Citigroup initiated coverage on shares of Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price for the company. Leerink Partners reduced their price objective on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. The Goldman Sachs Group cut Moderna from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.